US Pharma Marketing
For pharma, biotech, and life sciences commercial teams, marginal gains compound. The 5 items below distill what's working right now across HCP engagement, market access, patient services, and brand operations — drawn from current industry signal and what high-performing teams are quietly doing differently.
1. Wire it into your quarterly business review cadence
Pair this with a real-world evidence narrative and the payer conversation gets easier; ignore it and the formulary review gets harder.
2. Co-own the metrics with market access from day one
When this is wired into the planning cycle (not bolted on), forecast accuracy improves and launch readiness reviews become materially less painful.
3. Pressure-test against your top three competitive scenarios
The teams winning here have stopped treating market access and marketing as separate disciplines — they share the same dashboards and the same KPIs.
4. Build the measurement plan before you build the asset
Brands deploying this consistently report measurable lift in engagement quality, not just volume — the kind that translates to script behavior six to nine months downstream.
5. Pilot in one therapeutic area before scaling enterprise-wide
Top-quartile teams pair this with a tight measurement framework so the spend can be defended in the next zero-based budgeting cycle.
Putting It Into Practice
None of the items above are revolutionary on their own. The advantage comes from sequencing, measurement, and the discipline to retire activities that no longer move the business. Start with the two or three items most aligned to your next planning cycle, instrument them properly, and let the data decide what scales.
Related Industry Signal
- A new company rises from the ashes of Purdue Pharma — PharmaVoice
- What’s at stake in Amgen’s showdown with the FDA? — PharmaVoice
- Protein degraders gain speed as Arvinas scores landmark approval — PharmaVoice